{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T12:10:45Z","timestamp":1772539845773,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.chest.2020.09.247","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T14:11:51Z","timestamp":1601302311000},"page":"507-516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Approach to Eosinophilia Presenting With Pulmonary Symptoms"],"prefix":"10.1016","volume":"159","author":[{"given":"Chen E.","family":"Rosenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paneez","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.chest.2020.09.247_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2016.09.018","volume":"16","author":"Cottin","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.chest.2020.09.247_bib2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study group cohort","volume":"65","author":"Comarmond","year":"2013","journal-title":"Arthritis Rheumatism"},{"issue":"7","key":"10.1016\/j.chest.2020.09.247_bib3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management","volume":"26","author":"Groh","year":"2015","journal-title":"Eur J Intern Med"},{"issue":"20","key":"10.1016\/j.chest.2020.09.247_bib4","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.chest.2020.09.247_bib5","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.chest.2020.09.247_bib6","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jaip.2016.03.020","article-title":"Hypereosinophilia in children and adults: a retrospective comparison","volume":"4","author":"Williams","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.chest.2020.09.247_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaci.2010.03.042","article-title":"Refining the definition of hypereosinophilic syndrome","volume":"126","author":"Simon","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.chest.2020.09.247_bib8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/all.12843","article-title":"Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome","volume":"71","author":"Khoury","year":"2016","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.chest.2020.09.247_bib9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.iac.2007.07.002","article-title":"Lymphocytic variant hypereosinophilic syndromes","volume":"27","author":"Roufosse","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"issue":"11","key":"10.1016\/j.chest.2020.09.247_bib10","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/ajh.24880","article-title":"World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management","volume":"92","author":"Gotlib","year":"2017","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.chest.2020.09.247_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11882-015-0552-y","article-title":"Hypersensitivity to aspirin and other NSAIDs: diagnostic approach in patients with chronic rhinosinusitis","volume":"15","author":"Makowska","year":"2015","journal-title":"Curr Allergy Asthma Rep"},{"issue":"1","key":"10.1016\/j.chest.2020.09.247_bib12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12931-018-0909-6","article-title":"The utility of biomarkers in diagnosis of aspirin exacerbated respiratory disease","volume":"19","author":"Comhair","year":"2018","journal-title":"Respir Res"},{"issue":"4","key":"10.1016\/j.chest.2020.09.247_bib13","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.alit.2019.05.006","article-title":"Eosinophilic pneumonia: a review of the previous literature, causes, diagnosis, and management","volume":"68","author":"Suzuki","year":"2019","journal-title":"Allergol Int"},{"issue":"5","key":"10.1016\/j.chest.2020.09.247_bib14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00005792-199809000-00001","article-title":"Idiopathic chronic eosinophilic pneumonia: a clinical and follow-up study of 62 cases","volume":"77","author":"Marchand","year":"1998","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.chest.2020.09.247_bib15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1148\/radiol.2020192585","article-title":"Radiologic, pathologic, clinical, and physiologic findings of electronic cigarette or vaping product use-associated lung injury (EVALI): evolving knowledge and remaining questions","volume":"294","author":"Kligerman","year":"2020","journal-title":"Radiology"},{"issue":"9","key":"10.1016\/j.chest.2020.09.247_bib16","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1164\/rccm.2112056","article-title":"Idiopathic acute eosinophilic pneumonia: a study of 22 patients","volume":"166","author":"Philit","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.chest.2020.09.247_bib17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2500\/aap.2019.40.4262","article-title":"Allergic bronchopulmonary aspergillosis","volume":"40","author":"Patel","year":"2019","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"10.1016\/j.chest.2020.09.247_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/myc.12423","article-title":"Utility of IgE (total and Aspergillus fumigatus specific) in monitoring for response and exacerbations in allergic bronchopulmonary aspergillosis","volume":"59","author":"Agarwal","year":"2016","journal-title":"Mycoses"},{"key":"10.1016\/j.chest.2020.09.247_bib19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pupt.2017.07.002","article-title":"Non-asthmatic eosinophilic bronchitis and its relationship with asthma","volume":"47","author":"Lai","year":"2017","journal-title":"Pulmonol Pharmacol Ther"},{"issue":"13","key":"10.1016\/j.chest.2020.09.247_bib20","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006492","article-title":"Eotaxin and IL-4 levels are increased in induced sputum and correlate with sputum eosinophils in patients with nonasthmatic eosinophilic bronchitis","volume":"96","author":"Zhang","year":"2017","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.chest.2020.09.247_bib21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.iac.2015.05.003","article-title":"Eosinophilia in infectious diseases","volume":"35","author":"O\u2019Connell","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"issue":"6","key":"10.1016\/j.chest.2020.09.247_bib22","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/thx.2009.132217","article-title":"Parasitic infections of the lung: a guide for the respiratory physician","volume":"66","author":"Kunst","year":"2011","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.chest.2020.09.247_bib23","doi-asserted-by":"crossref","first-page":"e9688","DOI":"10.1097\/MD.0000000000009688","article-title":"Drug-induced eosinophilic pneumonia: a review of 196 case reports","volume":"97","author":"Bartal","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.chest.2020.09.247_bib24","doi-asserted-by":"crossref","first-page":"7863815","DOI":"10.1155\/2019\/7863815","article-title":"Pulmonary manifestations of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review","volume":"2019","author":"Taweesedt","year":"2019","journal-title":"Biomed Res Int"},{"issue":"3","key":"10.1016\/j.chest.2020.09.247_bib25","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaip.2017.01.025","article-title":"Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice","volume":"5","author":"Peter","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.chest.2020.09.247_bib26","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.jaci.2018.11.041","article-title":"Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis","volume":"143","author":"Steinfeld","year":"2019","journal-title":"J\u00a0Allergy Clin Immun"},{"issue":"7","key":"10.1016\/j.chest.2020.09.247_bib27","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","article-title":"Going from evidence to recommendation-determinants of a recommendation\u2019s direction and strength","volume":"66","author":"Andrews","year":"2013","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"12","key":"10.1016\/j.chest.2020.09.247_bib28","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/rheumatology\/kez139","article-title":"Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial","volume":"58","author":"Pu\u00e9chal","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.chest.2020.09.247_bib29","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/art.40205","article-title":"Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial","volume":"69","author":"Pu\u00e9chal","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.chest.2020.09.247_bib30","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1093\/rheumatology\/keu427","article-title":"Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis","volume":"54","author":"Grayson","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.chest.2020.09.247_bib31","series-title":"Benralizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) study (BITE). NCT03010436. ClinicalTrials.gov","year":"2017"},{"key":"10.1016\/j.chest.2020.09.247_bib32","series-title":"Efficacy and safety of benralizumab in EGPA compared to mepolizumab (MANDARA). NCT04157348. ClinicalTrials.gov","year":"2019"},{"issue":"1","key":"10.1016\/j.chest.2020.09.247_bib33","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaip.2017.06.006","article-title":"Hypereosinophilic syndrome subtype predicts responsiveness to\u00a0glucocorticoids","volume":"6","author":"Khoury","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.chest.2020.09.247_bib34","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.jaip.2018.04.033","article-title":"Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome","volume":"6","author":"Kuang","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"12","key":"10.1016\/j.chest.2020.09.247_bib35","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.chest.2020.09.247_bib36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/pai.12809","article-title":"Mepolizumab-a novel option for the treatment of hypereosinophilic syndrome in childhood","volume":"29","author":"Schwarz","year":"2018","journal-title":"Pediatr Allergy Immunol"},{"issue":"4","key":"10.1016\/j.chest.2020.09.247_bib37","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jaci.2010.06.049","article-title":"Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome","volume":"126","author":"Roufosse","year":"2010","journal-title":"J\u00a0Allergy Clin Immun"},{"key":"10.1016\/j.chest.2020.09.247_bib38","series-title":"Efficacy and safety study of mepolizumab in subjects with severe hypereosinophilic syndrome (HES). NCT02836496. ClinicalTrials.gov","year":"2016"},{"issue":"14","key":"10.1016\/j.chest.2020.09.247_bib39","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2020.09.247_bib40","series-title":"A phase 3 study to evaluate the efficacy and safety of benralizumab in patients with hypereosinophilic syndrome (HES) (NATRON). NCT04191304. ClinicalTrials.gov","year":"2019"},{"issue":"6","key":"10.1016\/j.chest.2020.09.247_bib41","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.jaci.2009.01.069","article-title":"Treatment of FIP1L1\/PDGFRA-negative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody","volume":"123","author":"Wagner","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.chest.2020.09.247_bib42","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.clml.2012.09.018","article-title":"Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody","volume":"13","author":"Strati","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.chest.2020.09.247_bib43","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jid.2016.10.044","article-title":"Treatment of hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors tofacitinib and ruxolitinib","volume":"137","author":"King","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.chest.2020.09.247_bib44","series-title":"Tyrosine kinase inhibition to treat myeloid hypereosinophilic syndrome. NCT00044304. ClinicalTrials.gov","year":"2002"},{"issue":"11","key":"10.1016\/j.chest.2020.09.247_bib45","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00277-015-2451-7","article-title":"Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene","volume":"94","author":"Rumi","year":"2015","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.chest.2020.09.247_bib46","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00277-014-2221-y","article-title":"Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes","volume":"94","author":"Schwaab","year":"2015","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.chest.2020.09.247_bib47","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/alr.22520","article-title":"Aspirin desensitization therapy in aspirin-exacerbated respiratory disease: a systematic review","volume":"10","author":"Larivee","year":"2020","journal-title":"Int Forum Allergy Rhinol"},{"issue":"2","key":"10.1016\/j.chest.2020.09.247_bib48","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.anai.2010.05.020","article-title":"Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease","volume":"105","author":"Lee","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.chest.2020.09.247_bib49","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2500\/aap.2019.40.4241","article-title":"Effect of omalizumab on outcomes in patients with aspirin-exacerbated respiratory disease","volume":"40","author":"Jean","year":"2019","journal-title":"Allergy Asthma Proc"},{"issue":"3","key":"10.1016\/j.chest.2020.09.247_bib50","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaip.2018.01.038","article-title":"A\u00a0retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease","volume":"6","author":"Tuttle","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.chest.2020.09.247_bib51","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.jaip.2019.03.044","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"10209","key":"10.1016\/j.chest.2020.09.247_bib52","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.chest.2020.09.247_bib53","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1378\/chest.12-2035","article-title":"Can omalizumab be effective in chronic eosinophilic pneumonia?","volume":"143","author":"Domingo","year":"2013","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2020.09.247_bib54","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1378\/chest.11-1881","article-title":"Omalizumab as a steroid-sparing agent in chronic eosinophilic pneumonia","volume":"142","author":"Kaya","year":"2012","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2020.09.247_bib55","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1183\/13993003.01475-2015","article-title":"A\u00a0randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma","volume":"47","author":"Agarwal","year":"2016","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2020.09.247_bib56","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.chest.2018.01.005","article-title":"A\u00a0randomized trial of itraconazole vs\u00a0prednisolone in acute-stage allergic bronchopulmonary aspergillosis complicating asthma","volume":"153","author":"Agarwal","year":"2018","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.chest.2020.09.247_bib57","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJM200003163421102","article-title":"A\u00a0randomized trial of itraconazole in allergic bronchopulmonary aspergillosis","volume":"342","author":"Stevens","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.chest.2020.09.247_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.465","article-title":"Allergic bronchopulmonary aspergillosis complicated by eosinophilic chronic rhinosinusitis successfully treated with mepolizumab","volume":"7","author":"Matsumoto","year":"2019","journal-title":"Respirol Case Rep"},{"issue":"6","key":"10.1016\/j.chest.2020.09.247_bib59","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2500\/aap.2015.36.3909","article-title":"Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: one center\u2019s experience with 14 cases","volume":"36","author":"Ayd\u0131n","year":"2015","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.chest.2020.09.247_bib60","series-title":"A study to evaluate the efficacy and safety of dupilumab in participants with allergy bronchopulmonary aspergillosis (ABPA) (LIBERTY ABPA AIRED). NCT04442269. clinicalTrials.gov","year":"2020"},{"issue":"8","key":"10.1016\/j.chest.2020.09.247_bib61","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1016\/j.jaip.2019.05.011","article-title":"Pediatric hypereosinophilia: characteristics, clinical manifestations, and diagnoses","volume":"7","author":"Burris","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.chest.2020.09.247_bib62","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.2214\/AJR.16.17315","article-title":"A\u00a0review of clinical and imaging findings in eosinophilic lung diseases","volume":"208","author":"Bernheim","year":"2017","journal-title":"AJR Am J Roentgenol"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369220348054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369220348054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:28:48Z","timestamp":1757924928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369220348054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0012369220348054"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2020.09.247","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Approach to Eosinophilia Presenting With Pulmonary Symptoms","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2020.09.247","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}